GOSS · Gossamer Bio, Inc.

This listing non-compliance notice signals heightened regulatory risk and potential loss of exchange visibility, liquidity, and institutional investor eligibility. The $1.00 bid price deficiency reflects sustained market valuation pressure, possibly tied to clinical, commercial, or financial developments not disclosed in this filing. While Nasdaq provides a clear remediation path — including a possible second 180-day grace period with a market transfer — qualification for that extension requires affirmative action: transferring to the Nasdaq Capital Market and certifying compliance with all other initial listing standards, such as minimum market value of publicly held shares. The Staff’s upcoming assessment of the Company’s likelihood to cure introduces uncertainty, as their negative determination could accelerate delisting proceedings. An appeal to the Nasdaq Hearing Panel offers procedural recourse but no assurance of success. For investors, this event elevates governance and liquidity risk, may trigger index exclusions, and could constrain future capital-raising options — particularly if the stock trades below $1.00 through the compliance window without a definitive remediation plan like a reverse stock split, which the Company explicitly notes as a potential tool.